Business Description
Pliant Therapeutics Inc
NAICS : 541714
SIC : 2833
ISIN : US7291391057
Share Class Description:
PLRX: Ordinary SharesTotal Employee Number:
49Compare
Compare
Traded in other countries / regions
PLRX.USA9PT.Germany Index Membership
Russell 2000Russell 2000Russell 3000 IPO Date
2020-06-03Description
Pliant Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the discovery and development of integrin-based therapies. The company operates as a single reportable segment focused on developing and commercializing novel integrin-based treatments. Its lead product candidate, PLN-101095, is an oral small molecule targeting integrins for the treatment of solid tumors. The company also advances a pipeline of integrin-based programs across multiple disease areas through its proprietary drug discovery platform.
Financial Strength
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 5.94 | |||||
Equity-to-Asset | 0.82 | |||||
Debt-to-Equity | 0.17 | |||||
Debt-to-EBITDA | -0.26 | |||||
Piotroski F-Score | 4/9 | |||||
WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year EBITDA Growth Rate | 6.3 | |||||
3-Year EPS without NRI Growth Rate | 6.5 | |||||
3-Year FCF Growth Rate | 2.9 | |||||
3-Year Book Growth Rate | -22.8 | |||||
Future 3-5Y EPS without NRI Growth Rate Estimate Industry Rank | 26.76 |
Momentum Rank
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 23.7 | |||||
9-Day RSI | 34.01 | |||||
14-Day RSI | 38.27 | |||||
3-1 Month Momentum % | 0.81 | |||||
6-1 Month Momentum % | 2.48 | |||||
12-1 Month Momentum % | -4.62 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 16.89 | |||||
Quick Ratio | 16.89 | |||||
Cash Ratio | 16.5 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -7.9 | |||||
Shareholder Yield % | 22.4 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
ROE % | -55.29 | |||||
ROA % | -41.96 | |||||
ROIC % | -315.5 | |||||
3-Year ROIIC % | -157.13 | |||||
ROC (Joel Greenblatt) % | -386.96 | |||||
ROCE % | -44.37 | |||||
Moat Score | 4 | |||||
Tariff Resilience Score | 7 |
GF Value Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PB Ratio | 0.43 | |||||
Price-to-Tangible-Book | 0.42 | |||||
EV-to-EBIT | 0.64 | |||||
EV-to-EBITDA | 0.65 | |||||
EV-to-Forward-Revenue | 17.3 | |||||
EV-to-FCF | 0.72 | |||||
| Price-to-Net-Current-Asset-Value | 0.5 | |||||
| Price-to-Net-Cash | 0.52 | |||||
Earnings Yield (Greenblatt) % | 156.25 | |||||
FCF Yield % | -139.98 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:PLRX
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Pliant Therapeutics Inc Executives
DetailsGF Valueâ„¢
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | |||
| EPS (TTM) ($) | -1.84 | ||
| Beta | 1.0453 | ||
| 3-Year Sharpe Ratio | -0.86 | ||
| 3-Year Sortino Ratio | -0.98 | ||
| Volatility % | 46.62 | ||
| 14-Day RSI | 38.27 | ||
| 14-Day ATR ($) | 0.047128 | ||
| 20-Day SMA ($) | 1.16325 | ||
| 12-1 Month Momentum % | -4.62 | ||
| 52-Week Range ($) | 1.09 - 1.95 | ||
| Shares Outstanding (Mil) | 61.92 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 4 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Pliant Therapeutics Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Pliant Therapeutics Inc Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| Third quarter earnings results for 2026 | 2026-11-06 | In 132 days | ||
| Second quarter earnings results for 2026 | 2026-08-07 | In 41 days | ||
| General meeting for 2026 | 2026-06-11 08:30 | 1.16 (-3.33%) | ||
| Guidance call for 2026 | 2026-05-19 11:30 | 1.18 (+0.85%) | ||
| First quarter earnings results for 2026 | 2026-05-11 | 1.22 (-2.40%) | ||
| Annual report for 2025 | 2026-03-11 | 1.39 (+7.75%) | ||
| Fourth quarter earnings results for 2025 | 2026-03-11 | 1.39 (+7.75%) | ||
| Oppenheimer 36th Annual Healthcare Life Sciences Conference | 2026-02-25 14:40 | 1.27 (+4.10%) | ||
| Piper Sandler Healthcare Conference | 2025-12-04 12:30 | 1.54 (+2.67%) | ||
| Third quarter earnings results for 2025 | 2025-11-06 | 1.64 (+1.86%) |
Show
Entries
Pliant Therapeutics Inc Frequently Asked Questions
What is Pliant Therapeutics Inc(PLRX)'s stock price today?
The current price of PLRX is $1.12. The 52 week high of PLRX is $1.95 and 52 week low is $1.09.
When is next earnings date of Pliant Therapeutics Inc(PLRX)?
The next earnings date of Pliant Therapeutics Inc(PLRX) is 2026-08-07 Est..
Does Pliant Therapeutics Inc(PLRX) pay dividends? If so, how much?
Pliant Therapeutics Inc(PLRX) does not pay dividend.
Guru Commentaries on NAS:PLRX
No articles.
Press Release
Articles on Pliant Therapeutics Inc
No articles.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers